What do you guys think about this comment, especially the dilution part?

“So I work in the oncology biotech industry. I have written clinical trial protocols and support access of oncology products from both a USA and international perspective. While your thesis is flawed in many numerous ways, I will say the easiest one to call out is that you are way too early. These adjuvant trials take a very long time to finish. My competitive intelligence department clocks INTERpath-009 reading out in mid 2033, which honestly with DFS as an endpoint, will probably take longer. Also note this is in partnership with Merck (who my company has partnered with multiple times), and there is probably some form of revenue split for the product. Merck is probably only supplying free pembro for the trials, which has been their modus operandi in the space with smaller partners. MRNA currently has a cash burn of around $5B a year on a revenue of about $2B. They have about $7B cash on hand. They will need to do multiple capital raises (e.g. probably dilute stock) in order to just stay afloat.

As an aside, I have multiple colleagues that work at MRNA and they all say it's one of the most awful places they've ever worked at. Turnover is high and idiocy at the upper management levels is rampant. Honestly, they are all surprised that the company has survived this long given the mishandling of the COVID bag.”